These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27511598)

  • 1. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
    Suresh PS; Devaraj VC; Srinivas NR; Mullangi R
    Biomed Chromatogr; 2017 Jan; 31(1):. PubMed ID: 27511598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
    Gu R; Liu T; Zhu X; Gan H; Wu Z; Li J; Zheng Y; Dou G; Meng Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():181-6. PubMed ID: 26245362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics and histone deacetylase inhibitors.
    Goey AK; Sissung TM; Peer CJ; Figg WD
    Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of an LC-MS/MS method for simultaneous detection of four HDAC inhibitors - belinostat, panobinostat, rocilinostat and vorinostat in mouse plasma and its application to a mouse pharmacokinetic study.
    Giri KK; Suresh PS; Saim SM; Zainuddin M; Bhamidipati RK; Dewang P; Hallur MS; Rajagopal S; Rajagopal S; Mullangi R
    Biomed Chromatogr; 2017 Jul; 31(7):. PubMed ID: 27925271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
    Kiesel BF; Parise RA; Tjørnelund J; Christensen MK; Loza E; Tawbi H; Chu E; Kummar S; Beumer JH
    J Pharm Biomed Anal; 2013; 81-82():89-98. PubMed ID: 23644904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood.
    Liu L; Detering JC; Milde T; Haefeli WE; Witt O; Burhenne J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Aug; 964():212-21. PubMed ID: 24636840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.
    Peer CJ; Hall OM; Sissung TM; Piekarz R; Balasubramaniam S; Bates SE; Figg WD
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):565-570. PubMed ID: 29951694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.
    Srinivas NR
    Xenobiotica; 2017 Apr; 47(4):354-368. PubMed ID: 27226420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.
    Chua MJ; Arnold MS; Xu W; Lancelot J; Lamotte S; Späth GF; Prina E; Pierce RJ; Fairlie DP; Skinner-Adams TS; Andrews KT
    Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):42-50. PubMed ID: 28107750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of chidamide in rat plasma and cerebrospinal fluid.
    Yang H; Li C; Chen Z; Mou H; Gu L
    Regul Toxicol Pharmacol; 2018 Oct; 98():24-30. PubMed ID: 30008379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UHPLC-MS-based HDAC Assay Applied to Bio-guided Microfractionation of Fungal Extracts.
    Zwick V; Allard PM; Ory L; Simões-Pires CA; Marcourt L; Gindro K; Wolfender JL; Cuendet M
    Phytochem Anal; 2017 Mar; 28(2):93-100. PubMed ID: 27921344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies.
    Yeo P; Xin L; Goh E; New LS; Zeng P; Wu X; Venkatesh P; Kantharaj E
    Biomed Chromatogr; 2007 Feb; 21(2):184-9. PubMed ID: 17221921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
    Rasmussen TA; Schmeltz Søgaard O; Brinkmann C; Wightman F; Lewin SR; Melchjorsen J; Dinarello C; Østergaard L; Tolstrup M
    Hum Vaccin Immunother; 2013 May; 9(5):993-1001. PubMed ID: 23370291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.
    Shah RR
    Drug Saf; 2019 Feb; 42(2):235-245. PubMed ID: 30649740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.